RU2630905C2 - Комбинация синбиотиков для улучшения мозговой деятельности - Google Patents
Комбинация синбиотиков для улучшения мозговой деятельности Download PDFInfo
- Publication number
- RU2630905C2 RU2630905C2 RU2015120800A RU2015120800A RU2630905C2 RU 2630905 C2 RU2630905 C2 RU 2630905C2 RU 2015120800 A RU2015120800 A RU 2015120800A RU 2015120800 A RU2015120800 A RU 2015120800A RU 2630905 C2 RU2630905 C2 RU 2630905C2
- Authority
- RU
- Russia
- Prior art keywords
- glutamine
- oligosaccharides
- nutritional composition
- walk
- cognitive
- Prior art date
Links
- 230000006872 improvement Effects 0.000 title abstract description 7
- 230000007177 brain activity Effects 0.000 title abstract description 3
- 235000019722 synbiotics Nutrition 0.000 title description 17
- 239000000203 mixture Substances 0.000 claims abstract description 172
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 128
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 106
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 99
- 241000186012 Bifidobacterium breve Species 0.000 claims abstract description 97
- 235000016709 nutrition Nutrition 0.000 claims abstract description 85
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 60
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 58
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims abstract description 54
- 230000003542 behavioural effect Effects 0.000 claims abstract description 49
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 47
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 47
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 46
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 40
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 40
- 230000007815 allergy Effects 0.000 claims abstract description 38
- 230000003997 social interaction Effects 0.000 claims abstract description 37
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 claims abstract description 35
- 238000011161 development Methods 0.000 claims abstract description 32
- 230000003920 cognitive function Effects 0.000 claims abstract description 31
- 235000021342 arachidonic acid Nutrition 0.000 claims abstract description 27
- 229940114079 arachidonic acid Drugs 0.000 claims abstract description 27
- 206010061218 Inflammation Diseases 0.000 claims abstract description 26
- 230000001149 cognitive effect Effects 0.000 claims abstract description 26
- 230000004054 inflammatory process Effects 0.000 claims abstract description 26
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 24
- 150000001413 amino acids Chemical class 0.000 claims abstract description 23
- 108010016626 Dipeptides Proteins 0.000 claims abstract description 21
- 230000000968 intestinal effect Effects 0.000 claims abstract description 21
- 229940090949 docosahexaenoic acid Drugs 0.000 claims abstract description 20
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 19
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000002253 acid Substances 0.000 claims abstract description 15
- 235000019197 fats Nutrition 0.000 claims abstract description 14
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims abstract description 14
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims abstract description 11
- 230000003959 neuroinflammation Effects 0.000 claims abstract description 11
- 150000003272 mannan oligosaccharides Chemical class 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 107
- 206010036590 Premature baby Diseases 0.000 claims description 54
- 235000018102 proteins Nutrition 0.000 claims description 45
- 230000006886 spatial memory Effects 0.000 claims description 33
- 230000018109 developmental process Effects 0.000 claims description 31
- 230000001771 impaired effect Effects 0.000 claims description 31
- 238000011282 treatment Methods 0.000 claims description 22
- 235000013350 formula milk Nutrition 0.000 claims description 20
- 206010041092 Small for dates baby Diseases 0.000 claims description 18
- 230000002028 premature Effects 0.000 claims description 18
- 230000003247 decreasing effect Effects 0.000 claims description 16
- 235000020256 human milk Nutrition 0.000 claims description 16
- 235000014633 carbohydrates Nutrition 0.000 claims description 15
- 230000008133 cognitive development Effects 0.000 claims description 15
- 210000004251 human milk Anatomy 0.000 claims description 14
- 230000015654 memory Effects 0.000 claims description 12
- 230000006399 behavior Effects 0.000 claims description 11
- -1 sialic acid oligosaccharides Chemical class 0.000 claims description 10
- 235000013336 milk Nutrition 0.000 claims description 7
- 239000008267 milk Substances 0.000 claims description 7
- 210000004080 milk Anatomy 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 4
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 4
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000003362 replicative effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 32
- 208000026935 allergic disease Diseases 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 3
- 208000012657 Atopic disease Diseases 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 105
- 235000013305 food Nutrition 0.000 description 44
- 108010058846 Ovalbumin Proteins 0.000 description 33
- 229940092253 ovalbumin Drugs 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 31
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 28
- 239000000843 powder Substances 0.000 description 27
- 230000002829 reductive effect Effects 0.000 description 24
- 208000010668 atopic eczema Diseases 0.000 description 21
- 238000000034 method Methods 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 210000004556 brain Anatomy 0.000 description 20
- 201000010859 Milk allergy Diseases 0.000 description 18
- 208000009793 Milk Hypersensitivity Diseases 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 16
- 235000021196 dietary intervention Nutrition 0.000 description 15
- 208000019901 Anxiety disease Diseases 0.000 description 14
- 230000036506 anxiety Effects 0.000 description 14
- 102000007544 Whey Proteins Human genes 0.000 description 12
- 108010046377 Whey Proteins Proteins 0.000 description 12
- 235000020940 control diet Nutrition 0.000 description 12
- 230000007423 decrease Effects 0.000 description 12
- 230000001976 improved effect Effects 0.000 description 12
- 230000000172 allergic effect Effects 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 11
- 230000035764 nutrition Effects 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 235000021119 whey protein Nutrition 0.000 description 11
- 210000003608 fece Anatomy 0.000 description 10
- 235000005974 protein supplement Nutrition 0.000 description 10
- 229940116540 protein supplement Drugs 0.000 description 10
- 102000011632 Caseins Human genes 0.000 description 9
- 108010076119 Caseins Proteins 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 102100022297 Integrin alpha-X Human genes 0.000 description 9
- 206010070834 Sensitisation Diseases 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- 150000003904 phospholipids Chemical class 0.000 description 9
- 230000008313 sensitization Effects 0.000 description 9
- 230000012010 growth Effects 0.000 description 8
- 210000001320 hippocampus Anatomy 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 230000002269 spontaneous effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 7
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 7
- 229930182816 L-glutamine Natural products 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 239000005018 casein Substances 0.000 description 7
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 7
- 235000021240 caseins Nutrition 0.000 description 7
- 150000002190 fatty acyls Chemical group 0.000 description 7
- 210000000936 intestine Anatomy 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 6
- 102000009016 Cholera Toxin Human genes 0.000 description 6
- 108010049048 Cholera Toxin Proteins 0.000 description 6
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 6
- 102000014171 Milk Proteins Human genes 0.000 description 6
- 108010011756 Milk Proteins Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229920002774 Maltodextrin Polymers 0.000 description 5
- 239000013566 allergen Substances 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 206010009887 colitis Diseases 0.000 description 5
- 235000020247 cow milk Nutrition 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 5
- 229940107187 fructooligosaccharide Drugs 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000011785 micronutrient Substances 0.000 description 5
- 235000013369 micronutrients Nutrition 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- PMGDADKJMCOXHX-BQBZGAKWSA-N Arg-Gln Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O PMGDADKJMCOXHX-BQBZGAKWSA-N 0.000 description 4
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 4
- 229920001202 Inulin Polymers 0.000 description 4
- 206010067508 Low birth weight baby Diseases 0.000 description 4
- 102100025136 Macrosialin Human genes 0.000 description 4
- 239000005913 Maltodextrin Substances 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 4
- 229940029339 inulin Drugs 0.000 description 4
- 229940035034 maltodextrin Drugs 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 230000037023 motor activity Effects 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 206010003645 Atopy Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010014025 Ear swelling Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 102000007072 Nerve Growth Factors Human genes 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 229940127236 atypical antipsychotics Drugs 0.000 description 3
- 238000009227 behaviour therapy Methods 0.000 description 3
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 230000003925 brain function Effects 0.000 description 3
- 230000003930 cognitive ability Effects 0.000 description 3
- 235000013325 dietary fiber Nutrition 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 235000021323 fish oil Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 206010022694 intestinal perforation Diseases 0.000 description 3
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000021239 milk protein Nutrition 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000003900 neurotrophic factor Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 238000011870 unpaired t-test Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 208000002881 Colic Diseases 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 239000001188 FEMA 4487 Substances 0.000 description 2
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 206010070531 Foetal growth restriction Diseases 0.000 description 2
- 206010016946 Food allergy Diseases 0.000 description 2
- 101001066288 Gallus gallus GATA-binding factor 3 Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 102100036840 T-box transcription factor TBX21 Human genes 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004578 fetal growth Effects 0.000 description 2
- 208000030941 fetal growth restriction Diseases 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 238000010212 intracellular staining Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000013016 learning Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 2
- 230000007472 neurodevelopment Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- ZFTFOHBYVDOAMH-XNOIKFDKSA-N (2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxymethyl]-2-(hydroxymethyl)oxolane-2,3,4-triol Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(OC[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 ZFTFOHBYVDOAMH-XNOIKFDKSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000741973 Bifidobacterium breve DSM 20213 = JCM 1192 Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 208000009129 Ear Neoplasms Diseases 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 229920002670 Fructan Polymers 0.000 description 1
- RTVRUWIBAVHRQX-PMEZUWKYSA-N Fucosyllactose Chemical compound C([C@H]1O[C@@H]([C@H]([C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H]1O)O)OC)O[C@H]1OC[C@@H](O)[C@H](O)[C@@H]1O RTVRUWIBAVHRQX-PMEZUWKYSA-N 0.000 description 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
- OPINTGHFESTVAX-BQBZGAKWSA-N Gln-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N OPINTGHFESTVAX-BQBZGAKWSA-N 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 206010058490 Hyperoxia Diseases 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010021746 Infantile colic Diseases 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 238000012180 RNAeasy kit Methods 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000009225 cognitive behavioral therapy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 201000005356 cow milk allergy Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000020595 eating behavior Effects 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000001200 fecal consistency Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 235000014106 fortified food Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000021244 human milk protein Nutrition 0.000 description 1
- 230000000222 hyperoxic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003903 intestinal lesions Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 description 1
- 229940062780 lacto-n-neotetraose Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000021140 nondigestible carbohydrates Nutrition 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000157 polyfructose Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000008433 psychological processes and functions Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 102220066049 rs146636139 Human genes 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 230000007596 spatial working memory Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960002197 temoporfin Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/009—Sachets, pouches characterised by the material or function of the envelope
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pediatric Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261721833P | 2012-11-02 | 2012-11-02 | |
| EP12191171.3 | 2012-11-02 | ||
| EP12191171 | 2012-11-02 | ||
| US61/721,833 | 2012-11-02 | ||
| PCT/NL2013/050785 WO2014070016A2 (en) | 2012-11-02 | 2013-11-04 | Synbiotics combination for brain improvement |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015120800A RU2015120800A (ru) | 2016-12-27 |
| RU2630905C2 true RU2630905C2 (ru) | 2017-09-14 |
Family
ID=47148641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015120800A RU2630905C2 (ru) | 2012-11-02 | 2013-11-04 | Комбинация синбиотиков для улучшения мозговой деятельности |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9974816B2 (enExample) |
| EP (2) | EP2914136B1 (enExample) |
| CN (2) | CN104883908A (enExample) |
| AU (1) | AU2013338705B2 (enExample) |
| BR (1) | BR112015009579B1 (enExample) |
| ES (1) | ES2884223T3 (enExample) |
| IN (1) | IN2015DN03862A (enExample) |
| MY (1) | MY173726A (enExample) |
| PH (1) | PH12015500904B1 (enExample) |
| PL (1) | PL2914136T3 (enExample) |
| RU (1) | RU2630905C2 (enExample) |
| WO (1) | WO2014070016A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015160234A1 (en) * | 2014-04-17 | 2015-10-22 | N.V. Nutricia | Composition for brain improvement |
| US20150305359A1 (en) * | 2014-04-24 | 2015-10-29 | Mead Johnson Nutrition Company | Nutritional compositions directed to subjects having cow's milk protein allergies |
| WO2016013928A1 (en) * | 2014-07-24 | 2016-01-28 | N.V. Nutricia | Prevention or treatment of food allergy in infants and toddlers |
| EP3193886A1 (en) * | 2014-09-15 | 2017-07-26 | N.V. Nutricia | Reducing anxiety in progeny |
| WO2016046294A1 (en) * | 2014-09-25 | 2016-03-31 | Nestec S.A. | INFANT FORMULA SYSTEM WITH ADAPTIVE LEVELS OF HUMAN MILK OLIGOSACCHARIDES (HMOs) |
| RU2706963C2 (ru) * | 2014-11-26 | 2019-11-21 | Абботт Лаборэтриз | Молочная смесь, содержащая олигосахариды грудного молока, полиненасыщенные жирные кислоты, нуклеотиды и лютеин |
| CN108348493B (zh) | 2015-10-02 | 2022-03-29 | 荷兰纽迪希亚公司 | 甘氨酸用于过敏性患者的耐受性诱导 |
| BR112018010505B1 (pt) | 2015-12-15 | 2021-11-16 | Société des Produits Nestlé S.A. | Composições para bebês e crianças pequenas, e uso de uma mistura sintética de hmos |
| CN109069555B (zh) * | 2016-04-13 | 2022-07-26 | 株式会社明治 | 面向新生儿的用于改善脑功能的组合物 |
| JP6853821B2 (ja) * | 2016-05-31 | 2021-03-31 | 森永乳業株式会社 | 脳機能改善剤 |
| US10729707B2 (en) * | 2016-07-28 | 2020-08-04 | Fonterra Co-Operative Group Limited | Dairy product and process |
| EP3522894A1 (en) * | 2016-10-05 | 2019-08-14 | N.V. Nutricia | Normalization of the intestinal microbiota composition in infants or toddlers fed with an amino acid-based nutritional composition |
| JP6976965B2 (ja) * | 2016-11-29 | 2021-12-08 | 森永乳業株式会社 | アグリコン産生促進剤 |
| WO2018143793A1 (en) * | 2017-02-01 | 2018-08-09 | N.V. Nutricia | Dietary modulation of brain functioning |
| RU2019141902A (ru) * | 2017-05-24 | 2021-06-17 | Сосьете Де Продюи Нестле С.А. | Композиция, содержащая олигофруктозу (of), для применения в улучшении кратковременной памяти и получении других когнитивных преимуществ |
| EP3629769A1 (en) | 2017-05-24 | 2020-04-08 | Société des Produits Nestlé S.A. | Composition comprising human milk oligosaccharides (hmo) for use in the improvement of short term memory and other cognitive benefits |
| EP4159224A1 (en) * | 2017-06-30 | 2023-04-05 | N.V. Nutricia | Synbiotic composition for preventing chronic inflammation |
| WO2019068356A1 (en) * | 2017-10-06 | 2019-04-11 | N.V. Nutricia | PROMOTION OF COGNITIVE FUNCTIONS AFTER BIRTH OF CAESAREAN |
| ES3024358T3 (en) * | 2017-12-11 | 2025-06-04 | Nutricia Nv | Composition for use for treating delayed colonization by bifidobacterium after birth |
| WO2020012505A1 (en) | 2018-07-13 | 2020-01-16 | Council Of Scientific & Industrial Research | Synbiotic composition for improving immune response and antioxidant capacity during aging and a process for the preparation thereof |
| IT201900000043A1 (it) * | 2019-01-03 | 2020-07-03 | Watt S R L | Sostituto della prima colazione |
| CN110214887B (zh) * | 2019-06-28 | 2022-10-11 | 浙江大学 | 针对液体自冷型超高压杀菌的装置及方法 |
| JP7406325B2 (ja) * | 2019-08-08 | 2023-12-27 | 森永乳業株式会社 | 分離不安障害の予防又は改善のための組成物 |
| GB2590624B (en) * | 2019-12-20 | 2023-08-30 | Green Bioactives Ltd | Composition comprising one or more fructooligosaccharide(s) and L-theanine |
| EP3932415A1 (en) | 2020-07-01 | 2022-01-05 | Fundació Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta (IDIBGI) | Gut microbiota composition and uses thereof |
| CN113025677A (zh) * | 2021-03-12 | 2021-06-25 | 长春大学 | 一种以海参为原料制备免消化海参蛋白质的方法 |
| WO2022253819A1 (en) * | 2021-06-02 | 2022-12-08 | N.V. Nutricia | Supplement for human milk from allergic women |
| CN114533765B (zh) * | 2022-03-17 | 2023-08-25 | 江南大学 | 短双歧杆菌ccfm1025在调节幼年神经发育中的应用 |
| WO2024254188A2 (en) * | 2023-06-05 | 2024-12-12 | Infinant Health, Inc. | Methods for treating enteric injury |
| GB2632345A (en) * | 2023-08-03 | 2025-02-05 | Mjn Us Holdings Llc | Human milk fortifier micronutrient supplementation kit |
| WO2025027192A1 (en) * | 2023-08-03 | 2025-02-06 | Mjn U.S. Holdings Llc | Human milk fortifier micronutrient supplementation kit |
| WO2025058081A1 (ja) * | 2023-09-14 | 2025-03-20 | 江崎グリコ株式会社 | 総合注意力、認知柔軟性及び／又は実行機能を改善するための組成物 |
| WO2025242902A1 (en) * | 2024-05-24 | 2025-11-27 | N.V. Nutricia | Oligosaccharide mixture for brain development |
| WO2025257135A1 (en) * | 2024-06-10 | 2025-12-18 | N.V. Nutricia | Non-digestible oligosaccharide mixture for infants at risk of brain injury |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030138476A1 (en) * | 2000-02-14 | 2003-07-24 | Van Leeuwen Paulus Aluisius Marie | Use of glutamate and/or a glutamate precursor for the preparation of a nutritional or pharmaceutical preparation for the treatment or prevention of hyperpermeability or undesired permeability of the intestinal wall |
| US20070207132A1 (en) * | 2003-10-24 | 2007-09-06 | N.V. Nutricia | Synbiotic Composition For Infants |
| WO2008111832A1 (en) * | 2007-03-13 | 2008-09-18 | N.V. Nutricia | Method of improving skills with a composition comprising non-digestible saccharide |
| US20100278781A1 (en) * | 2007-06-15 | 2010-11-04 | Sander Hougee | Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide |
| US20110086809A1 (en) * | 2009-10-14 | 2011-04-14 | Joshua Anthony | Enteral Administration Of Arginine-Glutamine Dipeptide To Support Retinal, Intestinal, Or Nervous System Development |
| US20120171165A1 (en) * | 2010-12-31 | 2012-07-05 | Abbott Laboratories | Human milk oligosaccharides to promote growth of beneficial bacteria |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1065411C (zh) * | 1995-06-18 | 2001-05-09 | 侯润安 | 新型保健营养奶粉及其生产方法 |
| DE19961535A1 (de) | 1999-12-20 | 2001-07-05 | Vacuumschmelze Gmbh | Filteranordnung |
| FR2853908B1 (fr) | 2003-04-16 | 2005-06-03 | Gervais Danone Sa | Produit immunomodulateur obtenu a partir d'une culture de bifidobacterium et compositions le contenant |
| MX2007010466A (es) * | 2005-02-28 | 2007-10-11 | Nutricia Nv | Composicion nutricional con probioticos. |
| EP1776877A1 (en) * | 2005-10-21 | 2007-04-25 | N.V. Nutricia | Method for stimulating the intestinal flora |
| EP2845496A1 (en) * | 2006-08-04 | 2015-03-11 | SHS International Ltd. | Protein free formula with prebiotics |
| NL1033521C2 (nl) | 2007-03-08 | 2008-09-09 | Friesland Brands Bv | Kindervoedingen met geoptimaliseerde aminozuursamenstelling. |
| WO2008119012A2 (en) * | 2007-03-27 | 2008-10-02 | The Procter & Gamble Company | Methods and kits for administering probiotics |
| PT2285387E (pt) * | 2008-06-13 | 2016-02-09 | Nutricia Nv | Nutrição para a prevenção de infeções |
| WO2011017107A2 (en) | 2009-07-27 | 2011-02-10 | Virginia Commonwealth University | Microbubble assisted viral delivery |
| EP2308498A1 (en) * | 2009-09-30 | 2011-04-13 | Nestec S.A. | Administration of Bifidobacterium breve during infancy to prevent inflammation later in life |
| US20120219526A1 (en) | 2009-10-29 | 2012-08-30 | Nestec S.A. | Nutritional compositions comprising lactoferrin and probiotics and kits of parts thereof |
| EP2335502A1 (en) * | 2009-12-07 | 2011-06-22 | Nestec S.A. | An infant formula delivery system comprising probiotics and an infant nutritional formulation |
| US20110208153A1 (en) | 2010-02-24 | 2011-08-25 | John Alvey | Formulations and methods for nutrient delivery |
| US20130095204A1 (en) * | 2011-10-14 | 2013-04-18 | Zeina Jouni | Nutritional phytonutrient compositions |
| AU2013208359B2 (en) * | 2012-01-09 | 2016-08-25 | N.V. Nutricia | Glutamine enriched nutritional composition for preterm infants |
-
2013
- 2013-11-04 AU AU2013338705A patent/AU2013338705B2/en active Active
- 2013-11-04 CN CN201380069118.3A patent/CN104883908A/zh active Pending
- 2013-11-04 WO PCT/NL2013/050785 patent/WO2014070016A2/en not_active Ceased
- 2013-11-04 EP EP13795882.3A patent/EP2914136B1/en active Active
- 2013-11-04 BR BR112015009579A patent/BR112015009579B1/pt active IP Right Grant
- 2013-11-04 EP EP21175733.1A patent/EP3936134A1/en active Pending
- 2013-11-04 ES ES13795882T patent/ES2884223T3/es active Active
- 2013-11-04 US US14/440,299 patent/US9974816B2/en active Active
- 2013-11-04 PL PL13795882T patent/PL2914136T3/pl unknown
- 2013-11-04 RU RU2015120800A patent/RU2630905C2/ru active
- 2013-11-04 PH PH1/2015/500904A patent/PH12015500904B1/en unknown
- 2013-11-04 CN CN201711281376.4A patent/CN107853705A/zh active Pending
- 2013-11-04 IN IN3862DEN2015 patent/IN2015DN03862A/en unknown
- 2013-11-04 MY MYPI2015001127A patent/MY173726A/en unknown
-
2018
- 2018-05-02 US US15/969,401 patent/US20190076490A1/en not_active Abandoned
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030138476A1 (en) * | 2000-02-14 | 2003-07-24 | Van Leeuwen Paulus Aluisius Marie | Use of glutamate and/or a glutamate precursor for the preparation of a nutritional or pharmaceutical preparation for the treatment or prevention of hyperpermeability or undesired permeability of the intestinal wall |
| US20070207132A1 (en) * | 2003-10-24 | 2007-09-06 | N.V. Nutricia | Synbiotic Composition For Infants |
| WO2008111832A1 (en) * | 2007-03-13 | 2008-09-18 | N.V. Nutricia | Method of improving skills with a composition comprising non-digestible saccharide |
| US20100278781A1 (en) * | 2007-06-15 | 2010-11-04 | Sander Hougee | Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide |
| US20110086809A1 (en) * | 2009-10-14 | 2011-04-14 | Joshua Anthony | Enteral Administration Of Arginine-Glutamine Dipeptide To Support Retinal, Intestinal, Or Nervous System Development |
| US20120171165A1 (en) * | 2010-12-31 | 2012-07-05 | Abbott Laboratories | Human milk oligosaccharides to promote growth of beneficial bacteria |
Non-Patent Citations (1)
| Title |
|---|
| WO 2008111832 A1, 18.09.23008. * |
Also Published As
| Publication number | Publication date |
|---|---|
| PH12015500904B1 (en) | 2023-04-19 |
| US20150366919A1 (en) | 2015-12-24 |
| EP2914136A2 (en) | 2015-09-09 |
| AU2013338705A1 (en) | 2015-06-04 |
| MY173726A (en) | 2020-02-18 |
| WO2014070016A2 (en) | 2014-05-08 |
| BR112015009579A2 (pt) | 2017-07-04 |
| BR112015009579B1 (pt) | 2020-04-28 |
| US20190076490A1 (en) | 2019-03-14 |
| ES2884223T3 (es) | 2021-12-10 |
| EP2914136B1 (en) | 2021-05-26 |
| PH12015500904A1 (en) | 2015-07-13 |
| CN104883908A (zh) | 2015-09-02 |
| IN2015DN03862A (enExample) | 2015-10-02 |
| US9974816B2 (en) | 2018-05-22 |
| CN107853705A (zh) | 2018-03-30 |
| PL2914136T3 (pl) | 2021-11-29 |
| EP3936134A1 (en) | 2022-01-12 |
| WO2014070016A3 (en) | 2014-06-26 |
| RU2015120800A (ru) | 2016-12-27 |
| AU2013338705A2 (en) | 2015-06-04 |
| AU2013338705B2 (en) | 2017-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2630905C2 (ru) | Комбинация синбиотиков для улучшения мозговой деятельности | |
| ES2666491T5 (en) | Composition for use in the prevention and/or treatment of intestinal inflammation and/or in the recovery after intestinal injury and surgery | |
| AU2018274636B2 (en) | Composition comprising Human Milk Oligosaccharides (HMO) for use in the improvement of short term memory and other cognitive benefits | |
| JP2015503913A (ja) | 認知機能の発達のためのラクトバチルス・ロイテリｄｓｍ１７９３８ | |
| AU2019296552B2 (en) | Composition comprising human milk oligosaccharides for use in improving, enhancing, promoting or modulating a serotonergic function in the central nervous system | |
| US12303522B2 (en) | Composition comprising human milk oligosaccharides for use in improving, enhancing, promoting or modulating a gabaergic function in the central nervous system | |
| HK1203315A1 (en) | Lactobacillus reuteri dsm 17938 for the development of the enteric nervous system | |
| RU2716214C2 (ru) | Композиция для улучшения умственных способностей | |
| RU2819351C2 (ru) | Композиция, содержащая олигосахариды грудного молока, для применения в улучшении, усилении, стимулировании или модулировании серотонинергической функции в центральной нервной системе | |
| RU2810236C2 (ru) | Композиция, содержащая олигосахариды грудного молока, для применения в улучшении, усилении, стимуляции или модулировании гамкергической функции в центральной нервной системе | |
| RU2791622C2 (ru) | Композиция, содержащая олигосахариды грудного молока (огм), для применения в улучшении кратковременной памяти и получении других когнитивных преимуществ | |
| TW201333193A (zh) | 用於發育腸神經系統之洛德乳桿菌(Lactobacillus reuteri)DSM 17938 | |
| CN113163835A (zh) | 促进肠道发育的发酵配方物 |